摘要
目的探究解毒理肺汤联合可必特雾化吸入辅助治疗小儿肺炎支原体肺炎的疗效及安全性。方法选取2018年1月至2020年3月本院收治的150例肺炎支原体肺炎患儿作为研究对象,根据双盲随机对照原则分为常规组与研究组,每组75例。常规组采用可必特雾化吸入治疗,研究组在常规组基础上采用解毒理肺汤治疗。比较两组临床疗效、临床症状改善时间、治疗前后炎症水平及不良反应发生率。结果研究组治疗总有效率为92.00%,明显高于常规组的77.33%(P<0.05)。研究组临床症状改善时间均短于常规组(P<0.05)。治疗前,两组CRP、IL-8、WBC水平比较差异无统计学意义;治疗后,研究组CRP、IL-8、WBC水平均低于常规组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论解毒理肺汤联合可必特雾化吸入辅助治疗小儿肺炎支原体肺炎效果显著,能进一步减轻患儿临床症状,降低炎症水平,且未增加不良反应,安全可靠,值得临床推广应用。
Objective To explore the efficacy and safety of Jiedu Lifei decoction combined with Kebit nebulized inhalation in the treatment of children with Mycoplasma pneumoniae pneumonia.Methods 150 children with Mycoplasma pneumoniae pneumonia admitted to our hospital from January 2018 to March 2020 were selected as the research subjects,According to the principle of double-blind randomized control,they were divided into routine group and study group,with 75 cases in each group.The conventional group was treated with Kebite nebulized inhalation,and the research group was treated with Jiedu Lifei decoction on the basis of the conventional group.The clinical efficacy,clinical symptom improvement time,inflammation level before and after treatment and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the study group was 92.00%,which was significantly higher than 77.33%in the conventional group(P<0.05).The improvement time of clinical symptoms in the study group was shorter than that in the conventional group(P<0.05).Before treatment,there was no significant difference in the levels of CRP,IL-8,and WBC between the two groups;after treatment,the levels of CRP,IL-8,and WBC in the study group were lower than those in the conventional group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups.Conclusion Jiedu Lifei decoction combined with Kebite nebulized inhalation is effective in the treatment of children with Mycoplasma pneumoniae pneumonia.It can further reduce the clinical symptoms of children and reduce the level of inflammation without increasing adverse reactions.It is safe and reliable.It is worthy of clinical application.
作者
谢莹莹
鄂小军
张小芹
李怡
XIE Yingying;E Xiaojun;ZHANG Xiaoqin;LI Yi(Department of Pediatrics,Wuhan Asia General Hospital,Wuhan,Hubei,430022,China)
出处
《当代医学》
2021年第16期40-42,共3页
Contemporary Medicine
关键词
解毒理肺汤
可必特
雾化吸入
小儿肺炎
支原体
疗效
Jiedu Lifei decoction
Kebite
Nebulized inhalation
Pediatric pneumonia
Mycoplasma
Curative effect
